

# Prakash Deedwania

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11879782/prakash-deedwania-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74  
papers

7,419  
citations

34  
h-index

76  
g-index

76  
ext. papers

8,432  
ext. citations

8.8  
avg. IF

5.12  
L-index

#	Paper	IF	Citations
74	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.. <i>Circulation</i> , <b>2022</b> , CIR0000000000001040	16.7	15
73	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 139-147	16.2	16
72	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. <i>American Journal of Medicine</i> , <b>2021</b> , 134, e252-e263	2.4	5
71	Impact of the 2017 ACC/AHA guidelines on the prevalence of hypertension among Indian adults: Results from a cross-sectional survey. <i>International Journal of Cardiology: Hypertension</i> , <b>2020</b> , 7, 100055	1.6	2
70	Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. <i>Indian Heart Journal</i> , <b>2019</b> , 71, 309-313	1.6	49
69	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 586-593.e5	4.9	6
68	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 288-297	16.2	52
67	Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 359-369	12.3	12
66	Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. <i>American Heart Journal</i> , <b>2017</b> , 187, 78-87	4.9	13
65	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 859-863	3.2	2
64	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 7, 201-210	18.1	330
63	Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. <i>International Journal of Cardiology</i> , <b>2017</b> , 227, 462-466	3.2	13
62	Mechanical Circulatory Support and Rationale for Future Research-Reply. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 715-6	11.5	
61	Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. <i>Current Hypertension Reports</i> , <b>2016</b> , 18, 76	4.7	33
60	Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST). <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 17-24	7.6	8
59	Is Increased Use of Mechanical Circulatory Support Devices Justified? A Cause for Concern. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 1982-3	11.5	0
58	The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 1855-63	4.1	8

57	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Circulation</i> , <b>2015</b> , 132, 691-718	16.7	239
56	Frequent Atrial Premature Complexes and Their Association With Risk of Atrial Fibrillation. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1852-7	3	36
55	Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation. <i>International Journal of Angiology</i> , <b>2015</b> , 24, 105-12	1.1	3
54	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , <b>2015</b> , 38, 1777-803	14.6	271
53	Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 426.e1-9	2.4	26
52	Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 219-28	2.4	109
51	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. <i>Core Evidence</i> , <b>2015</b> , 10, 63-73	4.9	2
50	Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 715-21	2.4	28
49	Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 945-52	7.6	24
48	Racial differences in mortality in patients with advanced systolic heart failure: potential role of right ventricular ejection fraction. <i>International Journal of Cardiology</i> , <b>2014</b> , 177, 255-60	3.2	1
47	Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: a cross sectional study. <i>Indian Heart Journal</i> , <b>2014</b> , 66, 280-8	1.6	26
46	A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 231-7	3	4
45	Regional variations in cardiovascular risk factors in India: India heart watch. <i>World Journal of Cardiology</i> , <b>2012</b> , 4, 112-20	2.1	115
44	An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. <i>Core Evidence</i> , <b>2012</b> , 7, 49-59	4.9	10
43	The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. <i>Circulation: Cardiovascular Genetics</i> , <b>2012</b> , 5, 51-7		17
42	EBlocker use and clinical outcomes in stable outpatients with and without coronary artery disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 1340-9	27.4	284
41	Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. <i>Circulation</i> , <b>2012</b> , 125, 1979-87	16.7	114
40	An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs. <i>Reviews in Cardiovascular Medicine</i> , <b>2012</b> , 13, e89-104	3.9	

39	Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. <i>Cardiology Clinics</i> , <b>2011</b> , 29, 87-103	2.5	31
38	Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 63-9	15.1	30
37	Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. <i>Cardiology Clinics</i> , <b>2011</b> , 29, 47-70	2.5	18
36	Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating $\beta$ blockers. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 52-9	2.3	47
35	Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. <i>American Journal of Cardiology</i> , <b>2011</b> , 107, 1208-14	3	74
34	A propensity-matched study of the association of diabetes mellitus with incident heart failure and mortality among community-dwelling older adults. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 1747-53	3	10
33	Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. <i>Cardiology Clinics</i> , <b>2011</b> , 29, 137-56	2.5	35
32	Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 200-6	12.3	69
31	Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1477-90	59.2	493
30	Effect of nateglinide on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1463-76	59.2	358
29	Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 221-7	3	35
28	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Circulation</i> , <b>2009</b> , 119, 251-7	16.7	265
27	An overview of glycemic control in the coronary care unit with recommendations for clinical management. <i>Journal of Diabetes Science and Technology</i> , <b>2009</b> , 3, 1342-51	4.1	11
26	Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHEBUS study). <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 1495-9	3	27
25	Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 3E-9E	3	15
24	The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. <i>International Journal of Cardiology</i> , <b>2009</b> , 131, 305-12	3.2	7
23	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 298-304	15.1	272
22	Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. <i>Journal of the American Society of Hypertension</i> , <b>2009</b> , 3, 210-20		13

21	Reducing morbidity and mortality in high risk patients with statins. <i>Vascular Health and Risk Management</i> , <b>2009</b> , 5, 495-507	4.4	5
20	Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 1448-54	15.1	230
19	Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. <i>Circulation</i> , <b>2008</b> , 117, 1610-9	16.7	308
18	Diabetes and vascular disease. <i>Expert Review of Cardiovascular Therapy</i> , <b>2008</b> , 6, 127-38	2.5	13
17	Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. <i>Circulation</i> , <b>2008</b> , 117, 3002-9	16.7	357
16	Ambulatory ECG-based T-wave alternans predicts sudden cardiac death in high-risk post-MI patients with left ventricular dysfunction in the EPHEBUS study. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2008</b> , 19, 1037-42	2.7	76
15	Management of coronary artery disease in patients with type 2 diabetes mellitus. <i>Current Cardiology Reports</i> , <b>2007</b> , 9, 264-71	4.2	6
14	Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2007</b> , 2, 1131-9	6.9	210
13	Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). <i>Circulation</i> , <b>2007</b> , 115, 700-7	16.7	179
12	Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients. <i>Journal of Clinical Hypertension</i> , <b>2007</b> , 9, 883-8	2.3	4
11	Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. <i>Diabetes Care</i> , <b>2006</b> , 29, 1220-6	14.6	410
10	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. <i>Lancet, The</i> , <b>2006</b> , 368, 919-28	4.0	315
9	What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 252-9	15.1	87
8	How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2003</b> , 7, 264-75		12
7	Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 478-80	3	21
6	The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 42, 914-22	15.1	184
5	A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. <i>Journal of Cardiac Failure</i> , <b>2003</b> , 9, 354-63	3.3	137
4	Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). <i>Circulation</i> , <b>2002</b> , 105, 1182-8	16.7	70

3	Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. <i>American Heart Journal</i> , <b>2001</b> , 142, 502-11	4.9	100
2	Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 283, 1295-302	27.4	935
1	Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. <i>Drugs</i> , <b>1987</b> , 34, 311-49	12.1	74